Despite revenue and profit declines in the 2010 third quarter, AstraZeneca Plc has confirmed that core earnings per share for the year as a whole should show an increase from 2009. Restructuring and legal costs depressed the Q3 results.
Despite revenue and profit declines in the 2010 third quarter, AstraZeneca Plc has confirmed that core earnings per share for the year as a whole should show an increase from 2009. Restructuring and legal costs depressed the Q3 results.